The antibacterial activity of N-formimidoyl thienamycin was compared with those of cefotaxime, cefoperazone, and piperacillin against 536 clinical aerobic isolates.
Thienamycin is a new f3-lactam antibiotic produced by Streptomyces cattleya (6) . The parent compound, thienamycin, is highly active against anaerobic bacteria, Pseudomonas aeruginosa, and staphylococci (7, 10, 15 There were greater than fourfold differences between the MICs at 103 and 105 CFU when cefotaxixne was tested against M. morganii, Citrobacter sp., and Serratia sp. (Table 2 ). An inoculum effect was also observed for piperacillin when tested against S. aureus, P. vulgaris, and enterococci. At 105 CFU per well, piperacillin was bactericidal at its MIC, as has been previously reported (13) .
The MICs and MBCs for N-formimidoyl thienamycin recorded here compare closely to those previously reported (4, 8) . The MICs for Citrobacter sp. and P. vulgaris were higher than those reported by Kesado and co-workers (7). Compared with those studies in which thienamycin rather than N-formimidoyl thienamycin was used, the MICs with the stabilized form were consistently lower (10, 15) . The E. coli strains in this study were more susceptible to piperacillin than those in the study by 
